IMR Press / RCM / Volume 19 / Issue S1 / DOI: 10.3909/ricm19S1S0003
Open Access Review
Can We Cure Atherosclerosis?
Show Less
1 Departments of Epidemiology & Medicine, University of Iowa College of Public Health and Carver College of Medicine, Iowa City, IA
2 Department of Cardiology, University of Chicago Medicine, Chicago, IL
Rev. Cardiovasc. Med. 2018 , 19(S1), 20–24; https://doi.org/10.3909/ricm19S1S0003
Published: 20 January 2018
Abstract
Cardiovascular disease mortality rates have begun to rise in the United States. Based on the large body of supportive evidence, we propose a proof-of-concept, first-in-human trial to cure atherosclerosis: CURing Early ATHEROsclerosis (CURE ATHERO). This trial is based on a model of intensive induction therapy for extensive, if not complete, plaque regression, followed by intermittent maintenance therapy. An extensive body of evidence has demonstrated the causal role of apolipoprotein B lipoproteins in atherosclerosis progression and data suggest intensive low-density lipoprotein cholesterol (LDL-C) lowering may have a substantial impact on earlier stages of atherosclerosis. Compared with lifetime treatment to prevent atherosclerosis progression, this induction–intermittent treatment model will minimize costs and maximize adherence and safety.
Keywords
Atherosclerosis
Regression
Primary prevention
Familial hypercholesterolemia
Apolipoprotein B lipoproteins
PCSK9 monoclonal antibodies
Statins
Share
Back to top